Palbociclib Pfizer

Menu

Close

HomeAboutMode of actionEfficacyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)Real World EvidenceP-REALITY study designP-REALITY patients characteristicsP-REALITY real-world progression-free survivalP-REALITY overall survivalP-REALITY strengthsSafetyImportant Safety InformationSafetySafety overviewPooled ARsPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresPalbociclib long-term safetyGI and liver toxicitiesEffect of Palbociclib on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyDosingRecommended dosing scheduleRecommended dose modifications for AEsOne scheduled monitoring provisionMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
PALOMA-3 tumour control

Palbociclib Pfizer in combination with fulvestrant improved tumour response rates vs placebo + fulvestrant in 1st line and later lines, including patients with visceral metastases1,2

PALOMA-3 Tumour Response1​​​​​​​

In patients with prior resistance to ET and visceral metastases, ORR* was 28% for Palbociclib Pfizer in combination with fulvestrant (n=200) vs 6.7% with placebo + fulvestrant (n=104)2

Adapted from Palbociclib Pfizer SmPC.1Data cut-off date: October 23, 2015.Defined as confirmed complete response or partial response.3 Defined as confirmed complete response or partial response or stable disease for ≥24 weeks.3
Explore More PALOMA-2

See PALOMA-2 tumour response data

 Learn more
CBR = clinical benefit rate; FUL = fulvestrant; ITT = intention-to-treat; n = number of patients; ORR = objective response rate; PLA = placebo; SmPC = Summary of Product Characteristics.
References:Palbociclib Pfizer Summary of Product Characteristics.Turner NC, et al. Ann Oncol. 2018;29(3):669-680.Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
PALOMA-3

A broad range of patients with HR+/HER2- mBC are eligible for Palbociclib Pfizer + letrozole combination therapy

 See patient profiles

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.